FDA Advisory Panel Votes Favorably on the First of Its Kind Hybrid Hearing Device from Cochlear

CENTENNIAL, Colo., Nov. 11, 2013 /PRNewswire/ -- Cochlear Limited (ASX: COH), the global leader in implantable hearing solutions, announced today that an advisory committee to the US Food and Drug Administration (FDA) voted favorably on the Cochlear™ Nucleus® Hybrid™ L24 Implant System. This is a first of its kind system designed for the treatment of adults with severe to profound sensorineural hearing loss in the high frequencies and normal to only mild hearing loss in the low frequencies, often referred to as "ski-slope" hearing loss. The panel, comprised of leading physicians and researchers, voted in favor of the new Hybrid device based on substantial clinical evidence demonstrating the safety and efficacy of the Nucleus Hybrid System in patients who met the candidacy criteria. The FDA is not bound by the recommendations of its advisory committees, but will consider the guidance during the final review of the new Hybrid device.

(Logo: http://photos.prnewswire.com/prnh/20130531/LA23942)

"We are pleased with the panel's vote for the Nucleus Hybrid System," said Chris Smith, President of Cochlear Americas. "The notion of hybrid hearing is truly a novel one that addresses an unmet need for people with hearing loss by bridging the gap between hearing aids and cochlear implants. This first-of-its-kind technology consists of a unique combination of solutions to overcome high frequency hearing loss, which impairs a person's ability to hear voices clearly and understand speech in noise. This positive recommendation is an important first step to giving thousands of patients the opportunity to hear much better than was possible even with the most advanced hearing aids."

The Nucleus Hybrid System combines the natural hearing via acoustic amplification of low frequencies with the electrical stimulation of a cochlear implant for high frequencies in one device. It is designed to deliver patients superior quality and clarity of sound in even the most difficult hearing situations, especially hearing in noisy environments.

"The Nucleus Hybrid System is a technological breakthrough when it comes to treating patients with hearing loss," said Bruce J. Gantz, M.D., Head of the Department of Otolaryngology – Head and Neck Surgery at the University of Iowa Carver College of Medicine and Hybrid System clinical investigator. "This device will open the doors to a whole new way of hearing both acoustically and electrically for those patients who cannot be treated effectively today with hearing aids."

About Cochlear
Cochlear is the global leader in implantable hearing solutions. It has a dedicated global team of more than 2,700 people who deliver the gift of sound to those with hearing loss in over 100 countries. Its vision is to connect people, young and old, to a world of sound by offering life enhancing hearing solutions.

The Cochlear promise of "Hear now. And always" embodies the company's commitment to providing its recipients with their best possible hearing performance today and for the rest of their lives. For over 30 years Cochlear has helped hundreds of thousands of people either hear for the first time or reconnect them to their families, friends, workplaces and communities.

For more information, visit Cochlear.com.

SOURCE Cochlear Limited